For most injectable GLP-1 receptor agonists (such as semaglutide injections, dulaglutide, and liraglutide), food has minimal impact on drug absorption because the medication is delivered directly into subcutaneous tissue and absorbed into the systemic circulation independently of the gastrointestinal tract
Based on existing registry data (e.g., FDA and EMA data), the patient should be informed that while there is no clear evidence of teratogenicity, intensified prenatal monitoring is required
I reached my highest weight ever at 270+ pounds and kept telling myself I was okay with it, but eventually I realized I wanted to make a change
In the SURMOUNT-1 trial, tirzepatide produced average weight reductions of 15.0%, 19.5%, and 20.9% at studied doses compared with 3.1% with placebo over 72 weeks
When to discuss changes with your provider Contact your provider about dosing frequency if any of these apply: You have been on the same dose and frequency for 3+ months with no weight change Side effects are persistent and significantly affecting quality of life You want to transition from daily to less frequent dosing You have reached your weight loss goal and want to discuss maintenance You are switching between different GLP-1 formulations The process of switching between GLP-1 medications involves careful dose conversion and may require restarting titration
